CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated (CORT) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 89% planned / 11% discretionary
Largest single sale: $10.8M.
Where they traded
Last open-market purchase: March 17, 2026 , by BAKER G LEONARD JR .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Vieira Roberto Wandenkolk 7 fills | President, Oncology | Sell 10b5-1 | 58,333 | $110.76 | $6.5M | 38,975 −59.9% of holding | |
| Maduck Sean 3 fills | See Remarks | Sell 10b5-1 | 25,000 | $114.43 | $2.9M | 23,025 −52.1% of holding | |
| Park Kimberly | Director | Sell | 26,685 | $122.55 | $3.3M | None left | |
| Maduck Sean 2 fills | See Remarks | Sell 10b5-1 | 30,955 | $125.58 | $3.9M | 15,625 −66.5% of holding | |
| MAHONEY DAVID L 4 fills | Director | Sell 10b5-1 | 103,606 | $118.25 | $12.3M | 1,232,161 −7.8% of holding | |
| Robb Gary Charles | Chief Business Officer | Sell | 10,000 | $116.26 | $1.2M | 39,716 −20.1% of holding | |
| WILSON JAMES N 3 fills | Director | Sell 10b5-1 | 10,000 | $111.43 | $1.1M | 1,081,490 −0.9% of holding | |
| Maduck Sean | See Remarks | Sell 10b5-1 | 3,664 | $114.49 | $419.5K | 9,755 −27.3% of holding | |
| Guyer William 2 fills | Chief Development Officer | Sell 10b5-1 | 16,300 | $113.43 | $1.8M | 8,755 −65.1% of holding | |
| Maduck Sean | See Remarks | Sell 10b5-1 | 1,031 | $114.52 | $118.1K | 9,755 −9.6% of holding | |
| Guyer William | Chief Development Officer | Sell 10b5-1 | 3,700 | $113.12 | $418.6K | 3,985 −48.1% of holding | |
| Maduck Sean | See Remarks | Sell 10b5-1 | 20,305 | $114.70 | $2.3M | 9,755 −67.5% of holding | |
| Lyon Joseph Douglas | See Remarks | Sell | 1,540 | $114.16 | $175.8K | 5,495 −21.9% of holding | |
| Mokari Atabak 13 fills | Chief Financial Officer | Sell 10b5-1 | 80,000 | $114.71 | $9.2M | 91,930 −46.5% of holding | |
| Mokari Atabak 4 fills | Chief Financial Officer | Sell 10b5-1 | 40,000 | $87.71 | $3.5M | 48,211 −45.3% of holding | |
| WILSON JAMES N 4 fills | Director | Sell 10b5-1 | 10,000 | $88.30 | $883.0K | 1,093,464 −0.9% of holding | |
| Guyer William 2 fills | Chief Development Officer | Sell 10b5-1 | 20,000 | $93.13 | $1.9M | 4,937 −80.2% of holding | |
| Maduck Sean 3 fills | See Remarks | Sell 10b5-1 | 25,000 | $88.35 | $2.2M | 23,731 −51.3% of holding | |
| MAHONEY DAVID L | Director | Sell | 20,000 | $84.53 | $1.7M | 26,147 −43.3% of holding | |
| WILSON JAMES N 2 fills | Director | Sell 10b5-1 | 10,000 | $83.20 | $832.0K | 1,100,366 −0.9% of holding | |
| Mokari Atabak 4 fills | Chief Financial Officer | Sell 10b5-1 | 40,000 | $81.15 | $3.2M | 46,696 −46.1% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.